Here are a couple related threads:
http://ihatedialysis.com/forum/index.php?topic=264.msg1429#msg1429http://ihatedialysis.com/forum/index.php?topic=3198.msg48186#msg48186................
Help Protect Your Dialysis Patients
Patients at Special Risk
Both acute care and chronic dialysis patients are particularly vulnerable to catheter-related bloodstream infections (CRBSIs) and local infection due to a number of high-risk factors:
* The large-bore design of dialysis catheters causes increased bleeding and greater opportunity for bacteria growth.
* Immunosuppressed dialysis patients have a diminished natural capacity to fight infection.
Dialysis Catheter Infection Rate
Chronic 21.2%
Acute Care 8%
* Chronic Dialysis Catheters have an infection rate of 21.2%, or 1.6 per 1,000 catheter days.¹
o Patients are still at high risk of infection several weeks after insertion.
o Chronic dialysis catheters have the highest infection rate of all vascular access devices.¹
* Acute Care Dialysis Catheters have an infection rate of 8%, or 4.8 per 1,000 catheter days.¹
o Acute care dialysis catheters are designed for short-term use, usually with no built-in infection protection.¹
A Powerful Solution in the Fight Against Infection
BIOPATCH® Protective Disk is a non-toxic, non-irritating and easy-to-apply solution that consistently inhibits Staphylococcus aureus and S. epidermidis, the organisms most frequently associated with CRBSI and local infection.†
* Depending on patient and dressing condition, the use of BIOPATCH® can decrease the frequency of dressing changes for chronic dialysis catheters from every dialysis session to only once a week.
* BIOPATCH® will continue to protect against infection by releasing CHG for up to 7 days. (Be sure to follow your hospital's protocol with respect to dressing changes.)
* BIOPATCH® is also indicated for use with Continuous Abdominal Peritoneal Dialysis (CAPD), where patient compliance can be a serious issue.
†Not for use on premature infants or patients with known sensitivity to CHG. Safety and effectiveness in children under 16 years of age has not been established.
References
1. Maki DG, Kluger MD, Crnich CJ. The Risk of Bloodstream Infection in Adults With Different Intravascular Devices: A Systematic Review of 200 Published Prospective Studies. Mayo Clin Proc. 2006;81(9):1159-1171.